ELND005 in Patients With Mild to Moderate Alzheimer's Disease

http://clinicaltrials.gov/ct2/show/NCT00568776?term=elnd005&rank=1

This study is currently recruiting participants.
Verified by Elan Pharmaceuticals, December 2007

The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease.

Alzheimer Disease
Drug: ELND005
Drug: Placebo Control
Phase II

Ages Eligible for Study: 50 Years to 85 Years
Genders Eligible for Study: Both

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568776

Contacts
Contact: Study Coordinator 1-877-687-8839

Locations

United States, New Jersey
The Memory Enhancement Center of America, Inc. Recruiting
Long Branch, New Jersey, United States, 07740